4,591 Shares in Jazz Pharmaceuticals PLC $JAZZ Bought by Globeflex Capital L P

Globeflex Capital L P bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,591 shares of the specialty pharmaceutical company’s stock, valued at approximately $780,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vestal Point Capital LP purchased a new stake in Jazz Pharmaceuticals during the second quarter valued at $127,344,000. Goldentree Asset Management LP purchased a new stake in Jazz Pharmaceuticals during the third quarter valued at $149,597,000. Bank of New York Mellon Corp raised its stake in Jazz Pharmaceuticals by 160.2% during the fourth quarter. Bank of New York Mellon Corp now owns 1,161,857 shares of the specialty pharmaceutical company’s stock valued at $197,516,000 after purchasing an additional 715,361 shares in the last quarter. Schonfeld Strategic Advisors LLC raised its stake in Jazz Pharmaceuticals by 592.1% during the third quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock valued at $57,523,000 after purchasing an additional 373,383 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in Jazz Pharmaceuticals by 62.1% during the second quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock valued at $84,341,000 after purchasing an additional 304,463 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Truist Financial raised shares of Jazz Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Leerink Partners increased their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Piper Sandler increased their target price on shares of Jazz Pharmaceuticals from $232.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, May 22nd. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the company from $188.00 to $307.00 in a research note on Tuesday, May 19th. Finally, Bank of America increased their target price on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $242.65.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Heather Ann Mcsharry sold 2,000 shares of the firm’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.00, for a total value of $482,000.00. Following the transaction, the director owned 18,449 shares of the company’s stock, valued at $4,446,209. This trade represents a 9.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the completion of the transaction, the director directly owned 384,682 shares in the company, valued at $73,281,921. This represents a 1.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 12,028 shares of company stock worth $2,522,587. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Trading Up 4.0%

Shares of JAZZ opened at $240.06 on Friday. The company has a market cap of $15.06 billion, a P/E ratio of -11,997.00, a P/E/G ratio of 0.40 and a beta of 0.32. Jazz Pharmaceuticals PLC has a twelve month low of $105.00 and a twelve month high of $243.32. The company’s fifty day simple moving average is $212.12 and its 200-day simple moving average is $186.53. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The company had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. As a group, analysts expect that Jazz Pharmaceuticals PLC will post 21.33 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.